The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

  • End date
    Jan 25, 2024
  • participants needed
  • sponsor
    Jun Zhang
Updated on 25 July 2021
human papillomavirus
hpv vaccine
human papilloma virus vaccine
hpv test


The primary objective of this study is to evaluate the durability of protection of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine administered in females aged 18-45 years.


This is a follow-up study that is based on phase III clinical study of a recombinant human papillomavirus 16/18 bivalent vaccine in females aged 18-45 years (Unique Protocol ID: HPV-PRO-003, Identifiers: NCT01735006). The investigators will recruit people who have participated in phase III clinical study on Hebei Province before and to evaluate the durability of protection of the bivalent HPV vaccine on 90m and 114m after dose 1.

Condition Cervical Cancer, Disorders of cervix NOS, Uterine Cancer, Cervical Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia, Persistent Infection, Vulvar Dysplasia, cervical carcinoma, cervical intraepithelial neoplasms, cervical cancer, uterine, carcinoma of the cervix uteri, carcinoma of the cervix, cervix cancer, cancer of the cervix, carcinoma of cervix, Vaginal Intraepithelial Neoplasia
Treatment Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Clinical Study IdentifierNCT04969445
SponsorJun Zhang
Last Modified on25 July 2021


Yes No Not Sure

Inclusion Criteria

Participants who participated in the Phase III clinical study of a recombinant human papillomavirus 16/18 bivalent vaccine in females (Unique Protocol ID: HPV-PRO-003, Identifiers: NCT01735006) and received at least one dose
Participants can fully understand the study content and sign an informed consent form
Able to comply with the requests of the study

Exclusion Criteria

Participants used other HPV vaccine products (including both marketed and unmarketed vaccines) since participating in the Phase III clinical study
According to the investigator's judgment, there might be some medical, psychological, social or occupational factors which might impact on the individual to obey the protocol or sign the informed consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note